12 Best Japanese Stocks To Buy in 2025

Page 6 of 11

6. Takeda Pharmaceutical Company Limited (NYSE:TAK)

Number of Hedge Fund Holders: 12

Takeda Pharmaceutical Company Limited (NYSE:TAK), a global pharmaceutical firm, conducts research, development, manufacturing, marketing, and out-licensing of pharmaceutical products. The company focuses on a wide range of therapeutic areas, including cancer, uncommon illnesses, and gastrointestinal.

Takeda Pharmaceutical Company Limited (NYSE:TAK) has upgraded its fiscal year 2024 financial estimate, anticipating a 2.5% increase in revenues to JPY 4,590.0 billion on account of favorable foreign exchange rates, strong business growth, and slower generic erosion of VYVANSE in the United States. It is expected that net profit will improve by 73.5% to JPY 118 billion while operating profit will rise by 29.8% to JPY 344 billion.

According to Insider Monkey’s Q3 database, 12 hedge funds were bullish on Takeda Pharmaceutical Company Limited (NYSE:TAK), an increase from 10 funds in the last quarter. Israel Englander’s Millennium Management is the leading stakeholder of the company.

Page 6 of 11